The most common failure in automation is focusing on the robot or software. True success is determined by deeply understanding and codifying the entire process, including its environment and inherent variabilities. Getting the requirements right is the core challenge; the technology itself is secondary.

The primary bottleneck for successful AI implementation in large companies is not access to technology but a critical skills gap. Enterprises are equipping their existing, often unqualified, workforce with sophisticated AI tools—akin to giving a race car to an amateur driver. This mismatch prevents them from realizing AI's full potential.

While automation is crucial for ensuring consistent, replicable experiments by eliminating human variability, it risks removing the "irregularity" that can lead to unexpected breakthroughs. This creates a new design challenge: engineering for human ingenuity alongside automated systems.

Large pharma companies are discovering that implementing AI to solve one part of the drug development workflow, like target discovery, creates new bottlenecks downstream. The subsequent, non-optimized stages become overwhelmed, highlighting the need for a holistic, fully choreographed approach to AI adoption across the entire R&D pipeline.

Before implementing AI automation, you must validate and refine a process manually. Applying AI to a flawed system doesn't fix it; it just makes the system fail more efficiently and at a larger scale, wasting significant time and resources.

A common error is screening strains or media in a simple batch mode when the final process will be fed-batch. This mismatch leads to incorrect candidate ranking and selection, forcing teams to restart the development process once the error becomes apparent during scale-up.

Despite the push for more automation, a World Quality Report found that 47% of organizations reported more escaped defects as automation grew. This suggests that automation without strategic human oversight and systems thinking can degrade, not improve, quality.

The bottleneck for AI in drug development isn't the sophistication of the models but the absence of large-scale, high-quality biological data sets. Without comprehensive data on how drugs interact within complex human systems, even the best AI models cannot make accurate predictions.

AI tools can dramatically accelerate test execution but lack the contextual understanding to interpret results or assess business risk. An effective hybrid model has humans own the 'what' and 'why' (sense-making) while AI handles the 'how fast' (execution).